Compare ARI & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARI | HELP |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.4M | 862.2M |
| IPO Year | 2009 | 2020 |
| Metric | ARI | HELP |
|---|---|---|
| Price | $6.41 | $10.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $8.00 | ★ $40.19 |
| AVG Volume (30 Days) | ★ 3.0M | 1.7M |
| Earning Date | 10-29-2026 | 11-12-2026 |
| Dividend Yield | ★ 15.85% | N/A |
| EPS Growth | ★ 183.51 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $271,589,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.11 | $3.76 |
| 52 Week High | $11.24 | $15.15 |
| Indicator | ARI | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 48.71 | 38.52 |
| Support Level | $6.11 | $4.41 |
| Resistance Level | $7.00 | $14.35 |
| Average True Range (ATR) | 0.11 | 0.77 |
| MACD | 0.05 | -0.23 |
| Stochastic Oscillator | 84.29 | 8.68 |
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.